vs
Side-by-side financial comparison of QUALYS, INC. (QLYS) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
QUALYS, INC. is the larger business by last-quarter revenue ($175.3M vs $129.7M, roughly 1.4× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 10.1%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 9.6%).
Qualys, Inc. is an American technology firm based in Foster City, California, specializing in cloud security, compliance and related services.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
QLYS vs TVTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $175.3M | $129.7M |
| Net Profit | $53.1M | — |
| Gross Margin | 83.4% | 98.0% |
| Operating Margin | 33.6% | -25.0% |
| Net Margin | 30.3% | — |
| Revenue YoY | 10.1% | 73.4% |
| Net Profit YoY | 20.9% | — |
| EPS (diluted) | $1.47 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $175.3M | $129.7M | ||
| Q3 25 | $169.9M | $164.9M | ||
| Q2 25 | $164.1M | $114.4M | ||
| Q1 25 | $159.9M | $81.7M | ||
| Q4 24 | $159.2M | $74.8M | ||
| Q3 24 | $153.9M | $62.9M | ||
| Q2 24 | $148.7M | $54.1M | ||
| Q1 24 | $145.8M | $41.4M |
| Q4 25 | $53.1M | — | ||
| Q3 25 | $50.3M | $25.7M | ||
| Q2 25 | $47.3M | $-12.8M | ||
| Q1 25 | $47.5M | $-41.2M | ||
| Q4 24 | $44.0M | — | ||
| Q3 24 | $46.2M | $-54.8M | ||
| Q2 24 | $43.8M | $-70.4M | ||
| Q1 24 | $39.7M | $-136.1M |
| Q4 25 | 83.4% | 98.0% | ||
| Q3 25 | 83.6% | 99.0% | ||
| Q2 25 | 82.4% | 98.7% | ||
| Q1 25 | 81.9% | 94.3% | ||
| Q4 24 | 81.8% | 96.6% | ||
| Q3 24 | 81.3% | 97.4% | ||
| Q2 24 | 82.2% | 96.2% | ||
| Q1 24 | 81.3% | 96.4% |
| Q4 25 | 33.6% | -25.0% | ||
| Q3 25 | 35.3% | 15.1% | ||
| Q2 25 | 31.3% | -11.1% | ||
| Q1 25 | 32.4% | -52.2% | ||
| Q4 24 | 31.0% | -81.2% | ||
| Q3 24 | 29.2% | -89.3% | ||
| Q2 24 | 32.3% | -125.1% | ||
| Q1 24 | 30.7% | -336.5% |
| Q4 25 | 30.3% | — | ||
| Q3 25 | 29.6% | 15.6% | ||
| Q2 25 | 28.8% | -11.1% | ||
| Q1 25 | 29.7% | -50.4% | ||
| Q4 24 | 27.6% | — | ||
| Q3 24 | 30.0% | -87.1% | ||
| Q2 24 | 29.4% | -130.1% | ||
| Q1 24 | 27.2% | -328.9% |
| Q4 25 | $1.47 | $0.04 | ||
| Q3 25 | $1.39 | $0.28 | ||
| Q2 25 | $1.29 | $-0.14 | ||
| Q1 25 | $1.29 | $-0.47 | ||
| Q4 24 | $1.19 | $-0.71 | ||
| Q3 24 | $1.24 | $-0.70 | ||
| Q2 24 | $1.17 | $-0.91 | ||
| Q1 24 | $1.05 | $-1.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $250.3M | $93.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $561.2M | $114.8M |
| Total Assets | $1.1B | $605.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $250.3M | $93.0M | ||
| Q3 25 | $225.3M | $110.9M | ||
| Q2 25 | $194.0M | $75.2M | ||
| Q1 25 | $290.7M | $61.9M | ||
| Q4 24 | $232.2M | $58.5M | ||
| Q3 24 | $235.4M | $36.4M | ||
| Q2 24 | $281.2M | $32.3M | ||
| Q1 24 | $273.8M | $43.3M |
| Q4 25 | $561.2M | $114.8M | ||
| Q3 25 | $529.4M | $73.6M | ||
| Q2 25 | $508.2M | $32.7M | ||
| Q1 25 | $498.0M | $32.8M | ||
| Q4 24 | $477.1M | $59.1M | ||
| Q3 24 | $449.6M | $-30.5M | ||
| Q2 24 | $427.8M | $15.1M | ||
| Q1 24 | $404.2M | $74.1M |
| Q4 25 | $1.1B | $605.2M | ||
| Q3 25 | $1.0B | $538.6M | ||
| Q2 25 | $999.5M | $555.3M | ||
| Q1 25 | $996.5M | $548.8M | ||
| Q4 24 | $973.5M | $594.1M | ||
| Q3 24 | $908.3M | $504.4M | ||
| Q2 24 | $876.6M | $551.1M | ||
| Q1 24 | $861.8M | $663.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $75.7M | $60.7M |
| Free Cash FlowOCF − Capex | $74.9M | — |
| FCF MarginFCF / Revenue | 42.8% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | 1.42× | — |
| TTM Free Cash FlowTrailing 4 quarters | $304.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.7M | $60.7M | ||
| Q3 25 | $90.4M | $14.3M | ||
| Q2 25 | $33.8M | $5.0M | ||
| Q1 25 | $109.6M | $-42.2M | ||
| Q4 24 | $47.7M | $-35.7M | ||
| Q3 24 | $61.0M | $-42.5M | ||
| Q2 24 | $49.8M | $-40.2M | ||
| Q1 24 | $85.5M | $-119.0M |
| Q4 25 | $74.9M | — | ||
| Q3 25 | $89.5M | $14.2M | ||
| Q2 25 | $32.4M | — | ||
| Q1 25 | $107.5M | — | ||
| Q4 24 | $41.9M | — | ||
| Q3 24 | $57.6M | — | ||
| Q2 24 | $48.8M | $-40.3M | ||
| Q1 24 | $83.5M | — |
| Q4 25 | 42.8% | — | ||
| Q3 25 | 52.7% | 8.6% | ||
| Q2 25 | 19.8% | — | ||
| Q1 25 | 67.3% | — | ||
| Q4 24 | 26.3% | — | ||
| Q3 24 | 37.4% | — | ||
| Q2 24 | 32.8% | -74.5% | ||
| Q1 24 | 57.2% | — |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.5% | 0.1% | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 2.2% | 0.0% | ||
| Q2 24 | 0.7% | 0.2% | ||
| Q1 24 | 1.4% | 0.0% |
| Q4 25 | 1.42× | — | ||
| Q3 25 | 1.80× | 0.56× | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 2.31× | — | ||
| Q4 24 | 1.09× | — | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.14× | — | ||
| Q1 24 | 2.15× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QLYS
| Sales Channel Through Intermediary | $88.6M | 51% |
| Sales Channel Directly To Consumer | $86.7M | 49% |
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
